By The United States Government Accountability Office

Agencies at the federal, state, and local levels have facilities capable of analyzing emerging street drugs—psychoactive substances newly circulating in the drug market. For example, the Drug Enforcement Administration and U.S. Customs and Border Protection have forensic laboratories that can analyze seized drugs and identify emerging substances. Current laboratory-based technologies can detect and identify emerging street drugs when appropriate methods (protocols) and reference standards are available. Portable technologies can detect drugs at the point of seizure but face accuracy challenges due, in part, to user error. Technology manufacturers told GAO they are developing more lay-friendly user interfaces and operational methods.

From fiscal year 2019 through 2024, the Departments of Justice and Health and Human Services awarded a combined total of about $12.5 million in grants for the development of new methods and technologies for analyzing emerging street drugs. New methods and technologies may make laboratory processes more consistent, among other enhancements. Method development can be done on faster timelines than technology development.

While new methods and technologies could enhance some capabilities, forensic scientists face key challenges with analyzing emerging street drugs, including:

• Lack of resources. Laboratories GAO spoke to consistently referenced insufficient staffing and time.

• Unstandardized reporting. According to stakeholders, varying reporting requirements at thestate and local levels can lead to gaps in data.

• Limited information sharing. Law enforcement may not always share up-to-date information about emerging drugs with medical examiners and hospitals.

If these challenges could be addressed, laboratories could be in a better position to meet the nation’s needs for emerging drug analysis. However, GAO is not making recommendations to address these challenges because they are primarily faced by state and local laboratories.

By: Nathan P. Jones1 & W. Layne Dittmann2 & Jun Wu3 & Tyler Reese2

This study is a mixed methods case study of the Fernando Sanchez Organization (FSO) better known as the Tijuana Cartel in the 2008–2010 period, aimed at better understanding internal structures and the roles of individuals in crossborder polydrug networks under pressures from rivals and state leadership targeting. In addition to historical archival data to build a qualitative case study, it uses arrest warrant data (an emergency wiretap application and a Racketeering Influenced Corrupt Organizations Act or RICO indictment) from the FSO drug network investigation in order to visualize the structure of the cross border network and to explore research questions regarding the relationship between actor centrality/network topography metrics and variables of interest including organizational role, age, gender, number of prior arrests, location of criminal activity, and location of residence using social network analysis (SNA). Findings included: narcotics distributors, drug couriers, and enforcers for the network all had higher centrality in the network, age was only slightly negatively correlated with eigenvector centrality, gender had no bearing on centrality, the number of prior arrests also had no bearing on degree or betweenness centrality, but did positively correlate with eigenvector centrality. Findings also demonstrated faction subgroup analysis had considerable overlap with both law-enforcement-reported-address and location of criminal activity (coded as actor attributes). This finding suggests it may be possible to predict the location of criminal activity and residence through faction analysis in other binational trafficking networks.